transcriptomic analysis
Phase 2Biologic
transcriptomic analysis is one of 9 biologic programs targeting Juvenile Dermatomyositis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Juvenile Dermatomyositis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbApproved
Medrol
PfizerPhase 2
Olumiant
Eli LillyPhase 2
Rituxan
RochePhase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Pregnancy Test
AAssistance Publique - Hôpitaux de Paris
Phase 2
transcriptomic analysis
AAssistance Publique - Hôpitaux de Paris
Phase 2
Pharmacokinetics Study
AAssistance Publique - Hôpitaux de Paris
Phase 2
Anti-CD19 UCAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for transcriptomic analysis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details